Navigation Links
Biosensors Reports Financial Results for the Third Quarter of Fiscal Year 2013
Date:2/7/2013

SINGAPORE, Feb. 7, 2013 /PRNewswire/ -- Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, today announced financial results for its third fiscal quarter ("Q3 FY13") and nine months ended 31 December 2012 ("FY13 nine-month period").

Financial Performance and Recent Highlights:

  • In January, Biosensors received CE Mark approval for its polymer-free drug-coated stent (DCS), BioFreedom™; the Company has also commenced global patient enrollment for LEADERS FREE clinical study during the quarter
  • Biosensors has signed an OEM agreement for both coronary and peripheral drug-eluting balloons which will be marketed under Biosensors' brand name.  These products have obtained several regulatory approvals including CE mark and will be available to Biosensors for worldwide distribution
  • Recently, the Company successfully raised S$300 million (approximately US$240 million) from the issuance of 4.875% fixed rate notes due 2017 under its S$800 million Multicurrency Medium Term Note Programme
  • In Q3 FY13, Interventional Cardiology Products (IVP) sales, largely comprising drug-eluting stent (DES) sales, increased by 9% year-on-year. For the FY13 nine-month period, IVP sales grew 42% compared to the same period last year
  • Total revenue for the FY13 nine-month period increased 21% over the same period last year; in Q3 FY13, total revenue declined by 4% year-on-year due to lower royalty and licensing revenue
  • In Q3 FY13, gross margin on total product sales was 82%, improved from previous quarter's 80% and 70% in the same quarter last year

"We have a number of important and exciting developments recently, including the CE Mark approval of our next-generation p
'/>"/>

SOURCE Biosensors International Group, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Biosensors Reports Strong Sales and Profitability in the First Quarter of Fiscal Year 2013
2. Sigma-Aldrich Reports Record Full Year 2012 Results. Reports Q4 2012 Diluted EPS Of $0.96. Q4 2012 Sales Increased 7%. Full Year 2012 Adjusted Diluted EPS Was $3.85. Expects Full Year 2013 Adjusted Diluted EPS To Increase To $4.10 - $4.20.
3. Cambrex Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
5. Plaintiff in Prolift Vaginal Mesh Case Testifies She Can No Longer Work, Have Sex, or Function Normally, Rottenstein Law Group Reports
6. Mesa Labs Reports 18% Increase in Third Quarter Revenues
7. Cardinal Health Reports Fiscal 2013 Second-Quarter Results
8. Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. BRICS NPWT Market and Pressure Relief Devices Industry Analysis in New Research Reports at ReportsnReports.com
11. Trimedyne Reports Financial Results For The Quarter And Fiscal Year Ended September 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... 2013  Today, the National Patient Advocate Foundation acknowledges ... of Representatives recently approved a bill that would prohibit ... higher out-of-pocket fees for newer, more expensive oral anti-cancer ... more severe side-effects. However, the bill was amended to ... continue to be a barrier to patients with cancer ...
(Date:5/16/2013)... May 16, 2013  Amgen (NASDAQ: AMGN ) ... Tuesday, May 21, 2013, at the Sheraton New York Times ... at 10:00 a.m. Eastern Daylight Time. Joseph P. ... and Development at Amgen, will present at the conference. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. A ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... LONDON , March 17, 2010 Hikma Pharmaceuticals,today announced 2009 preliminary results with operating profits up 36% on the,back of a strong performance from its Middle East ... , ... ... ...
... 16 American pharmaceutical manufacturer Alpharma Inc. has agreed ... Act allegations in connection with the marketing of the morphine-based ... allegations that, between January 1, 2000 and ... induce them to promote or prescribe Kadian, and made misrepresentations ...
Cached Medicine Technology:Hikma 2009 Results Interviews With CEO and CFO 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 2Alpharma to Pay $42.5 Million to Resolve False Claims Act Allegations in Connection With Promotion of Drug Kadian 3
(Date:5/19/2013)... People in Minnesota have a great option ... offering its 28 Day Fat Loss Formula. The best ... of their own home. The product sells for $135 dollars ... be accessed here: http://altmanfitness.com/28-day-fat-loss-formula/ , “Bikini season is ... now, but after using the 28 Day Fat Loss Formula ...
(Date:5/19/2013)... New York (PRWEB) May 19, 2013 ... in a federal litigation now underway in U.S. District ... Case Management Order dated May 3rd, the Court has ... Nominee Pool to eight cases rather than four. The ... scheduled for Thursday, May 23rd. (In re: Actos Product ...
(Date:5/19/2013)... City, Utah (PRWEB) May 19, 2013 ... information on small business health insurance . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... start-ups, and the self-employed intrinsically know the value ...
(Date:5/19/2013)... According to a new market research report ... 2018): By Applications (Healthcare (Endoscopy, Radiology, Ophthalmology), Surveillance, ... IS, Infrared, X-Ray) And Geography" published by MarketsandMarkets, ... billion in 2012 and is expected to reach ... of 3.84% from 2013 to 2018. In terms ...
(Date:5/19/2013)... 19, 2013 These molecular diagnostics ... UK, Spain, Japan, Italy, Germany and France:, ... diagnostics laboratory practice, as well as key economic, ... market impact during the next five years. , ... biochip technologies, test formats, detection methodologies, trends in ...
Breaking Medicine News(10 mins):Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 2Health News:Zane Benefits Publishes New Information on Small Business Health Insurance 3Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 2Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 3Health News:Molecular Diagnostics Market - US, UK, Spain, Japan, Italy, Germany & France Analysis in New Research Report at ReportsnReports.com 4
... 31, 2008) Real-world use of a novel drug-eluting ... good clinical outcomes, according to one-year data from a ... focused on the sirolimus-eluting Excel stent, are being reported ... SCAI Annual Scientific Sessions in Partnership with ACC i2 ...
... 31, 2008) A large community-based registry of patients ... how long patients with complex coronary artery disease typically ... drug that prevents unwanted blood clots; why they stop ... decision. , The new data from the MATRIX ...
... Percutaneous coronary intervention (PCI) may be a reasonable ... the left main coronary artery, according to a study ... when stents and bypass surgery were used to restore ... were treated with stenting were more likely to need ...
... refined salt prompt consumers, food industry to consider ... benefits of natural sea ... chemicals over a dinner plate - yet that,s exactly what millions,of ... food,with refined table salt, says Mark Zoske, co-founder of SaltWorks, Inc.,( ...
... Teleconference Tuesday, April 1, 2008 at 9:30 AM EDT, ... Bulletin Board: MLSS), the recognized leader in,advanced injection technologies, ... fiscal year, ended December 31, 2007., Key ... System was formally unveiled to market at ...
... Pharmaceutical Holdings, Inc. (Amex: KUN ) ("China ... research, development, manufacture,and marketing of pharmaceutical, nutritional supplement ... ("PRC"), today announced it will,conduct a conference call ... 2008, to,discuss the Company,s financial results for the ...
Cached Medicine News:Health News:Registry unveils 'real-world' data on novel excel stent 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 2Health News:Matrix registry probes adherence to clopidogrel at 1 year 3Health News:Study finds support for PCI in unprotected left main disease 2Health News:Study finds support for PCI in unprotected left main disease 3Health News:SaltWorks, Inc. Advises Table Salt Alternatives 2Health News:Milestone Scientific Announces 2007 Year-End Results 2Health News:Milestone Scientific Announces 2007 Year-End Results 3Health News:Milestone Scientific Announces 2007 Year-End Results 4Health News:Milestone Scientific Announces 2007 Year-End Results 5Health News:Milestone Scientific Announces 2007 Year-End Results 6Health News:Milestone Scientific Announces 2007 Year-End Results 7Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. Schedules Conference Call to Discuss FY 2007 Results 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: